Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial

Background [177Lu]Lu–PSMA‐617 (177Lu‐PSMA‐617) plus protocol‐permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression‐free survival (rPFS) versus SOC in patients with prostate‐specific membrane antigen (PSMA)–positive metastatic castration‐resistant prostate canc...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2024-10, Vol.130 (20), p.3426-3435
Main Authors: Morris, Michael J., de Bono, Johann, Nagarajah, James, Sartor, Oliver, Wei, Xiao X., Nordquist, Luke T., Koshkin, Vadim S., Chi, Kim N., Krause, Bernd J., Herrmann, Ken, Rahbar, Kambiz, Vickers, Adrian, Mirante, Osvaldo, Ghouse, Ray, Fizazi, Karim, Tagawa, Scott T.
Format: Article
Language:English
Subjects:
177Lu‐PSMA‐617
Aged
Arm
Cancer therapies
Castration
Correlation analysis
Correlation coefficient
Correlation coefficients
health‐related quality of life (HRQOL)
Humans
Lutetium - therapeutic use
Lutetium isotopes
Male
Metastases
Metastasis
metastatic castration‐resistant prostate cancer (mCRPC)
Middle Aged
Neoplasm Metastasis
Progression-Free Survival
Prostate cancer
Prostate-specific antigen
Prostatic Neoplasms, Castration-Resistant - mortality
Prostatic Neoplasms, Castration-Resistant - pathology
Prostatic Neoplasms, Castration-Resistant - psychology
Quality of Life
radiographic progression‐free survival (rPFS)
Survival
Well being
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background [177Lu]Lu–PSMA‐617 (177Lu‐PSMA‐617) plus protocol‐permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression‐free survival (rPFS) versus SOC in patients with prostate‐specific membrane antigen (PSMA)–positive metastatic castration‐resistant prostate cancer (mCRPC) in the phase 3 VISION study, in addition to beneficial effects on symptomatic skeletal events (SSEs) and health‐related quality of life (HRQOL). Methods Post hoc analyses used the full analysis set from the VISION study (N = 831) overall and by randomized treatment arm (177Lu‐PSMA‐617 plus SOC, n = 551; SOC, n = 280). Correlations were determined between OS and rPFS and between rPFS or OS and time to SSE or to worsening HRQOL (Functional Assessment of Cancer Therapy–Prostate [FACT‐P] and 5‐level EQ‐5D [EQ‐5D‐5L]). Correlation analyses used an iterative multiple imputation copula‐based approach (correlation coefficients [rho] of 
ISSN:0008-543X
1097-0142
1097-0142
DOI:10.1002/cncr.35438